The TheraSphere® Advanced Dosimetry Retrospective Global Study Evaluation in Hepatocellular Carcinoma Treatment (TARGET) is designed to evaluate two-compartment dosimetry (normal tissue and tumor absorbed dose) in hepatocellular carcinoma patients to achieve a more personalized approach to Y90 radioembolization therapy for liver cancer patients.

The primary endpoint of the study will determine the correlation between the normal tissue absorbed dose, based on Tc-99m MAA, and grade ≥3 hyperbilirubinemia for patients administered TheraSphere®. Secondary endpoints in the TARGET study include: tumor absorbed dose, incidence of serious adverse events, select dose-related adverse events, clinical laboratory assessment, objective tumor response and overall survival.

The TARGET trial complements other studies that BTG is undertaking in interventional oncology (in collaboration with leading clinical and industry partners) with the ultimate goal of improving patient outcomes in HCC.